Rosuhol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rosuhol

Property Description
Active ingredient Rosuvastatin Calcium
Form Film-coated tablets, Oral preparation
Pharmacological class HMG-CoA reductase inhibitor (Statin)
General purpose Management of high cholesterol (Dyslipidemia)
Origin Synthetic compound

What Type of Medicine is Rosuhol?

Rosuhol is a prescription-only medicine whose active substance is Rosuvastatin, a compound derived through chemical synthesis. Rosuvastatin defines Rosuhol as a member of the pharmacological class of HMG-CoA reductase inhibitors, widely recognized as statins. This classification is clinically recognized for establishing a standard approach to lipid management, indicating its role as a systemic antilipemic agent designed for internal metabolic action. It is formulated as a single-ingredient product, focusing the therapeutic effect exclusively on the established actions of Rosuvastatin.

Composition and Form: What Does Rosuhol Contain?

The Rosuhol preparation is formulated for the oral route as film-coated tablets. The core chemical substance contained is Rosuvastatin Calcium, combined with the necessary solid pharmaceutical excipients that determine the tablet's structure and stability. Rosuvastatin is characterized by its high hepatic selectivity, meaning it preferentially targets the liver, the organ responsible for its primary metabolic action. This precise formulation is engineered to facilitate its selective systemic absorption.

What is the General Purpose of Rosuhol?

The general purpose of Rosuhol is to help individuals manage high cholesterol and related mixed dyslipidemia by intervening directly in the liver's metabolic pathway. Rosuvastatin accomplishes this by limiting the body's internal cholesterol synthesis and prompting the liver to enhance the clearance of harmful low-density lipoprotein cholesterol (LDL-C) from the bloodstream. This lipid-modifying action is a well-established strategy in cardiovascular health management to mitigate risks associated with elevated LDL-C levels.

Regulatory References

  1. Rosuvastatin: MedlinePlus Drug Information

What side effects are possible with Rosuhol?

Possible side effects and safety information

The safety profile of Rosuvastatin, the active substance in Rosuhol, is defined by official regulatory documents, classifying potential adverse reactions by frequency and the body system affected. These classifications organize documented effects from common to rare and very rare.

Commonly documented adverse reactions primarily involve the Nervous system (Headache, Dizziness), the Gastrointestinal system (Constipation, Nausea, Abdominal pain), and the Musculoskeletal system (Myalgia, or muscle pain). Asthenia (weakness) and elevations in hepatic transaminases are also listed as common findings.

Uncommon effects are mainly associated with the Skin and subcutaneous tissue disorders, including Pruritus (itching), Rash, and Urticaria (hives).

Rare and serious adverse reactions officially documented include Rhabdomyolysis (a serious muscle condition) and Pancreatitis. Hepatitis (liver inflammation) is classified as a very rare hepatobiliary disorder.

The regulatory safety profile includes population-specific considerations. Patients with renal impairment have an increased potential for myopathy. Increased systemic exposure is noted in patients of Asian descent. Rosuvastatin is contraindicated for use in individuals with active liver disease and during pregnancy and lactation. A dose-related safety pattern is noted, with proteinuria (protein in urine) being observed, particularly at higher dosages, a finding often described as transient.

Overdose and Emergency Response

Rosuhol Overdose and When to Seek Help

The official regulatory documentation for Rosuvastatin (the active ingredient in Rosuhol) specifies the course of action required following suspected overdosage. Immediate medical attention is required for any suspected overdose event; patients must contact emergency services or a Poison Control center immediately.

Documented Overdose Profile

While there is no specific symptom profile documented for acute overdosage, the primary concern is the potential for dose-dependent escalation of severe adverse reactions. The major documented risks include rhabdomyolysis (severe muscle damage) and secondary acute renal failure caused by the release of myoglobin into the kidneys.

Management and Emergency Actions

Official labeling mandates that treatment following an overdose must be symptomatic and supportive. Regulatory authorities confirm that no specific antidote is known for Rosuvastatin overdosage. Due to the drug’s extensive plasma protein binding, the regulatory note specifies that hemodialysis is not expected to be of benefit in overdose management. Ongoing monitoring, including measurements of Creatine Kinase (CK) levels and renal function, is required to assess for potential musculoskeletal and kidney complications.

Therapeutic Uses of Rosuhol

What Rosuhol Treats: Main Uses and Benefits

Rosuvastatin, the active ingredient in Rosuhol, is a medication commonly used to help with a central axis of systemic imbalance: the regulation of blood lipids. Its primary role may assist with managing conditions associated with an elevated risk of heart and blood vessel problems.

A key therapeutic domain is the management of hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia, which are conditions characterized by periods of heightened symptoms that can lead to cardiovascular events. Rosuvastatin contributes to easing the overall symptom load associated with blood lipid imbalance.

This medicine is applied in addressing situations where symptoms of cardiovascular risk become more noticeable. It is relevant for use in conditions such as hypercholesterolaemia (high cholesterol), mixed dyslipidaemia, and in clinical scenarios involving raised serum triglyceride levels. In contexts involving heightened systemic burden for a first cardiovascular event, Rosuvastatin provides support that helps ease the overall symptom burden.

“This medicine is relevant in contexts marked by increased discomfort or tension, and is applied across domains where additional symptomatic support is needed.”

Quick Fact: Support for Physiological Strain

It may assist with maintaining functional stability related to cardiovascular health and is relevant for easing symptoms linked to organ-specific functional stress caused by lipid disorders.

Eligibility and Restrictions for Use

Official Population Eligibility Rules for Rosuhol

Rosuhol (rosuvastatin) is subject to strict eligibility rules based on regulatory labeling, defining which populations are permitted or restricted from its use. Use is established for adults and for children and adolescents aged 6 years and older for specific lipid disorders, though use is not recommended for children younger than 6.


Absolute Contraindications

Rosuhol is contraindicated (absolutely must not be used) in several patient populations, including those with:

  • Active liver disease or persistent, unexplained elevations in liver enzymes.
  • Pregnancy or lactation (breastfeeding); females of reproductive potential must use effective contraception.
  • Active myopathy (muscle disease) or known hypersensitivity to any component.
  • Severe renal impairment (Creatinine clearance <30 mL/min/1.73 m^2).
  • Concomitant use with ciclosporin.

Restricted Use and Special Populations

Eligibility is limited for other groups. Use is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh score ge 7). A lower starting dose (5 mg) is recommended for patients over 70 years of age and for patients of Asian descent due to differences in drug exposure. Use requires caution in patients with factors predisposing them to myopathy, such as uncontrolled hypothyroidism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Rosuhol (Rosuvastatin) is defined by mandatory restrictions and conditions for co-administration, as specified in official regulatory documents.

Interaction Category Specific Interacting Substances Official Regulatory Constraint
Contraindicated Combinations Ciclosporin, Systemic Fusidic Acid Formally prohibited due to significant increase in rosuvastatin exposure or heightened risk of muscle-related effects.
Additive Muscle Risk Fibrates (e.g., Gemfibrozil), Niacin (ge 1 g/day), Colchicine Documented to increase the risk of adverse skeletal muscle effects (myopathy/rhabdomyolysis).
Exposure-Altering Agents Specific Antivirals (e.g., Lopinavir/Ritonavir), Darolutamide, Regorafenib Increase rosuvastatin plasma concentration, necessitating strict dosage limits defined in regulatory labels.
Timing Separation Aluminum and Magnesium Hydroxide Antacids Must be administered at least two hours after Rosuhol to prevent documented reduction in drug absorption.

Transporter-mediated interactions are documented as the main pharmacokinetic cause of elevated exposure; rosuvastatin is a substrate for the OATP1B1 and BCRP transporters. The inhibition of these transporters establishes the need for careful risk management with many co-administered medicines. The use of Rosuhol with Coumarin Anticoagulants (such as Warfarin) is documented to prolong the International Normalized Ratio (INR), requiring procedural monitoring. Official documentation also notes that Asian patients may have higher baseline systemic exposure, a population-specific factor relevant to interaction risk assessment.

Mechanism of Action

How Rosuhol Works

The action of Rosuhol is defined by its active ingredient, Rosuvastatin, which operates through a precise, enzyme-based cascade focused on hepatic lipid regulation.

Targeting the Rate-Limiting Enzyme: HMG-CoA Reductase

Rosuvastatin acts as a competitive inhibitor of the enzyme HMG-CoA Reductase ( HMGR) in the liver. By blocking HMGR, the drug suppresses the rate-limiting step of the mevalonate pathway, thereby limiting the liver's internal cholesterol biosynthesis. This inhibition initiates the biochemical cascade that modifies systemic lipid dynamics.

Activating Systemic LDL Clearance Mechanisms

This initial molecular interaction causes a drop in intracellular cholesterol. In response, the hepatocyte is signaled to up-regulate the synthesis and surface expression of Low-Density Lipoprotein Receptors ( LDL-R). These enhanced receptors substantially increase the liver's capacity to capture and remove LDL-C particles from the bloodstream, resulting in a physiological reduction in circulating LDL-C concentration.

Mechanistic Limitations

Since the drug’s core action relies on the functionality of the LDL-R clearance pathway, the mechanism is constrained or functionally overridden in biological states, such as genetic defects where the LDL-R is non-functional.

Dosage and Administration Information

How to Use Rosuhol (Rosuvastatin): Administration Guidelines

Rosuhol is a prescription-only medicine for oral use only, formulated as film-coated tablets in strengths of 5 mg, 10 mg, 20 mg, and 40 mg. The dosage is designed for once daily administration and is typically a long-term treatment.


Standard Dosing and Frequency

Regimen Feature Guideline
Route of Administration Oral. The tablet must be swallowed whole and should not be crushed or chewed.
Timing and Food Can be taken at any time of day, with or without food.
Usual Starting Dose (Adults) 10 mg or 20 mg once daily.
Dose Adjustment Dose changes, if necessary, should be made at intervals of 2 to 4 weeks based on patient response.
Maximum Dose 40 mg once daily. This dose is reserved for patients who have not achieved their target goals on 20 mg and may require specialized supervision upon initiation in some regions.

Population-Specific Use Rules

Prescribing information outlines specific dosing considerations for certain populations due to expected differences in drug exposure:

  • Patients with Severe Renal Impairment (not on hemodialysis): The recommended starting dose is 5 mg once daily and should not exceed 10 mg once daily.
  • Asian Patients: A starting dose of 5 mg is advised due to increased rosuvastatin plasma concentrations. The maximum recommended dose is often limited to 20 mg in this population.
  • Older Adults (over 70 years of age): A 5 mg starting dose may be recommended in some regions.

If a dose is missed, the patient should not take an extra dose to make up for the missed one, but should simply resume treatment with the next scheduled dose. If taking an aluminum/magnesium hydroxide antacid, Rosuhol should be administered at least 2 hours before the antacid to ensure proper absorption.

Recent Clinical Evidence

Rosuhol: Recent Clinical Evidence

This summary provides an overview of clinical research concerning rosuvastatin (the active ingredient in Rosuhol), focusing on studies investigating its association with changes in lipid profiles and cardiovascular outcomes. Consultation with a healthcare provider is important for interpreting whether these findings apply to individual health situations.


Pharmacological and Mechanistic Studies

Rosuvastatin belongs to the class of HMG-CoA reductase inhibitors (statins). Research has explored its high affinity for the enzyme HMG-CoA reductase, which plays a role in cholesterol production in the liver. Studies indicate that this inhibition leads to an increase in LDL-receptor expression, subsequently increasing the clearance of LDL cholesterol from the bloodstream. Further research has explored the association between the drug and overall outcomes in the target patient population.


Clinical Trial Findings

Clinical research has centered on the findings related to primary endpoints for symptom control and lipid management across diverse patient groups.

Efficacy and Lipid Profile

Primary clinical trials examined the changes in key lipid parameters associated with the drug compared to a control group (e.g., placebo or active comparator). These trials assessed the drug's impact on reducing Low-Density Lipoprotein (LDL) cholesterol, often referred to as 'bad' cholesterol, and total cholesterol. Secondary findings included the effects on High-Density Lipoprotein (HDL) cholesterol and triglycerides. Findings regarding the consistency of the results across different patient subsets were mixed.

Safety and Tolerability

The drug’s safety profile was assessed in large-scale adult clinical trials. In placebo-controlled studies, the frequency of adverse events was comparable between the rosuvastatin and placebo groups. The most commonly reported findings related to adverse events in the trials included headache and mild gastrointestinal discomfort, and sometimes muscle aches. Studies have identified potential risks or interactions in patient populations with pre-existing conditions, which underscores the need for careful risk assessment. Long-term safety data is ongoing, with current data describing the adverse event profile throughout the studied periods.

Frequently Asked Questions (FAQ)

Common questions about Rosuhol (FAQ)

Q: How quickly does Rosuhol start working to affect my cholesterol numbers?

Initial changes associated with Rosuhol use are documented to begin within the first week of starting the medication. According to official product information, the maximum reduction in LDL cholesterol is generally observed about four weeks after beginning regular treatment.

Q: Why do some people say they feel tired when taking Rosuhol?

Weakness, which is formally described in regulatory documents as asthenia, is described in official documentation as a common adverse reaction. This finding is included in the official safety profile for the medication.

Q: Does taking Rosuhol require regular blood tests?

Official guidelines describe that a fasting lipid profile and liver enzymes are typically checked before beginning therapy. A follow-up lipid profile is typically obtained within four to twelve weeks after starting treatment or changing the dose to check its effectiveness.

Q: What other common medications, besides antifungals, interact with Rosuhol?

Documented interactions involve medicines such as the immunosuppressant Ciclosporin (contraindicated), specific antivirals (protease inhibitors), and other lipid-lowering agents like Gemfibrozil or high-dose Niacin. These substances can increase the concentration of Rosuhol in the bloodstream, which may require careful monitoring.

Q: How long after starting Rosuhol will my doctor check my cholesterol levels?

Regulatory documents indicate that the first follow-up test to assess the medicine’s effectiveness on lipid levels is typically recommended within four to twelve weeks after starting treatment or changing the dosage.

Q: What is Rosuhol actually used for besides lowering cholesterol?

Approved uses extend beyond lowering general cholesterol to include the reduction of specific blood fat types like triglycerides and managing certain genetic conditions. The medicine is also indicated for preventative strategies, such as reducing the risk of stroke and myocardial infarction in certain high-risk individuals.

Q: What happens if I stop taking Rosuhol suddenly?

Official prescribing information does not detail a specific physical withdrawal syndrome upon sudden cessation. However, the medicine is generally a long-term treatment, and stopping it without medical direction can cause cholesterol levels to return to previous high levels. This may be associated with an increase in the underlying cardiovascular risk factors.

Q: Can Rosuhol cause joint or muscle pain?

Official safety documents indicate that muscle pain (myalgia) is listed in regulatory documents as a common side effect. Joint pain (arthralgia) is also reported among other adverse effects observed in patients.

Q: Is Rosuhol the same as Crestor?

Rosuhol and Crestor contain the same active medicinal substance, which is rosuvastatin. Crestor is the registered brand name for the drug. Both formulations are regulated to ensure they deliver the same active ingredient.

Q: Are there any long-term effects of taking Rosuhol for many years?

Clinical research has examined long-term use. Official long-term data indicates that the drug is generally consistent with its established safety profile over extended periods. However, some studies have noted a potential small increased risk for new-onset Type 2 diabetes and cataract formation in certain individuals.

Q: What are the most common reasons someone is told they cannot take Rosuhol?

Official documentation lists absolute contraindications, including having active liver disease, being pregnant or breastfeeding, having a known hypersensitivity to the ingredients, or taking the immunosuppressant Ciclosporin. These conditions represent absolute contraindications for its use.

Q: Does Rosuhol have any interactions with common supplements like CoQ10?

Official sources state that there is currently no clear evidence on the effects or benefits of taking Coenzyme Q10 (CoQ10) alongside rosuvastatin. More research is indicated to clarify any potential relationship.

Q: Is it normal to have mild stomach upset when starting Rosuhol?

Mild gastrointestinal discomfort is a commonly reported finding. Official documentation lists adverse reactions such as nausea, constipation, and abdominal pain that may occur.

Q: Can Rosuhol be taken with alcohol?

Rosuhol may affect the liver, and official warnings note that consumption of substantial quantities of alcohol may increase the risk of liver effects.

Q: Can Rosuhol cause memory problems or confusion?

Cognitive issues like memory loss and confusion have been reported during post-marketing surveillance for statins. These effects are generally described as non-serious and are usually reversible once the medication is stopped.

Q: Does Rosuhol interact with grapefruit?

Unlike some other statins, rosuvastatin is minimally metabolized by the liver enzymes that are affected by grapefruit. Due to this difference in how the body processes the drug, official prescribing information does not typically include a prominent warning regarding grapefruit consumption.

Q: Is Rosuhol commonly prescribed for people who already had a heart attack?

The drug is indicated for use in cardiovascular disease management, which includes reducing the risk of a heart attack (myocardial infarction) and slowing the progression of atherosclerosis in adults.

Q: How is Rosuhol eliminated from the body?

The active substance, rosuvastatin, is not extensively metabolized in the body. It is primarily eliminated from the body via the liver and is removed mostly unchanged through the feces.

Q: Can Rosuhol affect my sleep?

Sleep-related issues have been reported during post-marketing experience. These include instances of sleeplessness (insomnia) and the occurrence of nightmares.

Q: Is there evidence that Rosuhol helps with inflammation?

Clinical research has explored non-lipid-lowering effects, often referred to as pleiotropic properties. Studies have indicated evidence of reduced inflammation at the site of coronary plaque.

Q: Why is Rosuhol sometimes prescribed in combination with ezetimibe?

This combination is used because it targets two different mechanisms to lower cholesterol. Rosuvastatin reduces cholesterol production in the liver, while ezetimibe works by reducing the absorption of cholesterol from the diet in the intestine.

Q: How does Rosuhol compare to lifestyle changes alone?

Official documentation states that Rosuhol is indicated as an adjunct to diet and lifestyle changes. Such changes are considered an essential part of the overall treatment plan and work alongside the medicine's effects.

Q: Are generic versions of Rosuhol considered equivalent to the brand name?

Generic versions of Rosuhol (rosuvastatin) are regulated by health authorities and must demonstrate bioequivalence to the brand-name product. This means they must deliver the same amount of the active ingredient into the bloodstream in the same amount of time.

Q: Does Rosuhol interact with hormonal birth control?

Rosuvastatin may interact with certain hormonal contraceptives, potentially increasing the systemic concentration of the hormones within the bloodstream. Official information details these potential interactions.

Q: Can people with kidney problems use Rosuhol?

Use is strictly contraindicated in patients with severe renal impairment (a measure of very low kidney function). For patients with less severe kidney problems, use may be considered, but a lower maximum daily dose may be recommended.

Q: Does Rosuhol cause hair loss?

Hair loss, or alopecia, is described in post-marketing reports as an uncommon adverse effect with the drug.

Q: What does 'dose-related increase in liver transaminases' mean?

This phrase refers to how the levels of certain liver enzymes (transaminases) are documented to potentially rise in the bloodstream. Official warnings indicate this finding is associated more frequently with higher dosages of the medicine.

Q: Is Rosuhol linked to an increased risk of cataracts?

Clinical trial data has described an association between rosuvastatin use and a potential small increase in the risk of requiring cataract surgery compared to some other statins.

Q: Does Rosuhol protect against stroke?

For certain adult patients who are at an increased risk of cardiovascular disease but do not yet have clinically evident coronary heart disease, the medication is indicated to reduce the risk of stroke.

Q: Is it okay to take Rosuhol with multivitamins?

Official documents do not list a general interaction with multivitamins. However, if a multivitamin contains an aluminum or magnesium hydroxide antacid, it should be taken at least two hours after Rosuhol to prevent reduced absorption.

Q: Why is Rosuhol considered a long-term treatment?

The medicine is generally prescribed as a long-term treatment because high cholesterol is typically a chronic condition. Sustained action is required to maintain low lipid levels and support long-term cardiovascular risk management.

Q: Can men taking Rosuhol experience sexual side effects?

While post-marketing reports have included sexual side effects, the evidence in large-scale clinical reviews does not suggest a convincing causal relationship between statin use and issues like erectile dysfunction.

How should Rosuhol be stored and disposed of?

Storage and Disposal Conditions for Rosuhol (Rosuvastatin)

Rosuhol, in film-coated tablet form, must be stored and handled according to regulatory requirements to maintain its stability and prevent accidental exposure.


Storage and Handling

Condition Requirement (Official Statement)
Temperature Store below 30 C; do not freeze.
Protection Protect from light and store in a dry place.
Packaging Keep the tablets in their original package with the lid tightly closed (if applicable).
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Disposal must follow local regulatory guidelines. Unused or expired Rosuhol must not be thrown away via wastewater or regular household waste. Instead, the product should be disposed of in accordance with local requirements, often by returning it to a pharmacist or designated waste collection scheme.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rosuhol found in:

A-Z Index: